Date:5/6/2011

nts include, but are not limited to, the following:  product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the fiscal year ended September 30, 2010.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.

'/>"/>

SOURCE The Female Health Company Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. The Female Health Company Declares 2nd Quarter Dividend of $0.05/share
2. The Me-Covery: Saatchi & Saatchi Wellness and Time Inc.s Health Brand Reveal Historic Shift in Female Consumer Behavior
3. Co-Promotion of a New Medical Device for Female Infertility Announced
4. The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup
5. Second-Generation Female Condom is Now Available in the United States; FC2 Female Condom Will Cost 30 Percent Less than Predecessor
6. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
7. Female Health Company Receives Brazilian Order: Four Million FC Female Condoms
8. New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence
9. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
10. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
11. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference